Compounded tirzepatide
Sold by Woodwork · every compounded tirzepatide record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
What you actually pay
Per month
$199
| Medication · Compounded GLP-1 + GIP (tirzepatide), starting price | $199 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Compounded GLP-1 + GIP (tirzepatide), starting price “Compounded GLP-1 + GIP Active ingredient: tirzepatide INJECTIONS From $199/mo*” | Per month$199 | Charged today$199 |
We earn nothing from this link. Woodwork has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
One reading so far. A price history appears here after the next verification pass.
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Pharmacy | Precision Compounding Pharmacy; TriadRX |
|---|---|
| States | Not disclosed as of September 3, 2026 |
| Prescriber | Asynchronous review |
| Cancellation | “You may cancel your subscription at any time either by clicking the CANCEL under Manage Your Subscription on the Woodwork Patient Portal, or by sending an email with your name and email address associated with the service to cancel@woodwork.com. To ensure a smooth process, please send your cancellation notice at least 72 hours in advance of your billing date.” |
Not yet checked: membership and consult fee.
Recorded from woodwork.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — Woodwork is 'Built by Grindr' (Grindr LLC), per footer/terms. Labs are described as 'recommended and included in the cost of your treatment' with no separate consult fee found.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.